IP Library Granted Patent US 8,563,023
Granted Patent B2
US 8,563,023 · App. 13/310,320 · Granted Oct 22, 2013

Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,023
App. No.
13/310,320
Granted
Oct 22, 2013
Kind
B2
Abstract

A method and device for local delivery of water-soluble or water-insoluble therapeutic agents to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which is complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue.

Claims (24)

1. A method of delivering a substantially water-insoluble therapeutic agent to a vascular lumen comprising: providing a catheter assembly having a non-durable coating disposed on an outer surface of an expandable structure of the catheter assembly, wherein the non-durable polymer coating is complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein; introducing the catheter assembly into a vascular lumen; expanding the expandable structure of the catheter assembly to contact the non-durable coating against the vascular lumen; and contracting the expandable structure.

2. The method of claim 1 , wherein the substantially water-insoluble therapeutic agent is selected from the group consisting of an anti-proliferative agent, anti-platelet agent, anti-inflammatory agent, anti-thrombotic agent, and thrombolytic agent.

3. The method of claim 2 , wherein at least 50% of the non-durable coating is dissolved within 180 seconds of the expanding.

4. The method of claim 3 , wherein at least 90% of the non-durable coating is dissolved within 300 seconds of the expanding.

5. The method of claim 2 , wherein the substantially water-insoluble therapeutic agent is paclitaxel.

6. The method of claim 5 , wherein at least 5% of the therapeutic agent contained in the non-durable coating is imparted into tissue of the vascular lumen within one hour of contracting the expandable structure.

7. The method of claim 6 , wherein at least 25% of the therapeutic agent contained in the non-durable coating is imparted into tissue of the vascular lumen within one hour of contracting the expandable structure.

8. The method of claim 1 , wherein the iodine is complexed with a polymer selected from the group consisting of polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP) and hydroxypropyl cellulose (HPC) in the non-durable coating.

9. The method of claim 1 , wherein the iodine is complexed with a polymer selected from the group consisting of methyl cellulose and hydroxypropyl methylcellulose, or a co-polymer of N-vinylpyrrolidone with a reactive double bond containing monomer.

10. A method of delivering a substantially water-insoluble therapeutic agent to a vascular lumen comprising:

providing a catheter assembly having a non-durable coating disposed on an outer surface of an expandable structure of the catheter assembly, wherein the non-durable coating comprises a substantially water-insoluble therapeutic agent dispersed amongst non-covalently bound iodine within a polymer matrix;

introducing the catheter assembly into a vascular lumen;

expanding the expandable structure of the catheter assembly to contact the non-durable coating against the vascular lumen; and

contracting the expandable structure.

11. The method of claim 10 , wherein the substantially water-insoluble therapeutic agent is selected from the group consisting of an anti-proliferative agent, anti-platelet agent, anti-inflammatory agent, anti-thrombotic agent, and thrombolytic agent.

12. The method of claim 11 , wherein at least 50% of the non-durable coating is dissolved within 180 seconds of the expanding.

13. The method of claim 12 , wherein at least 90% of the non-durable coating is dissolved within 300 seconds of the expanding.

14. The method of claim 11 , wherein the substantially water-insoluble therapeutic agent is paclitaxel.

15. The method of claim 14 , wherein at least 5% of the therapeutic agent contained in the non-durable coating is imparted into tissue of the vascular lumen within one hour of contracting the expandable structure.

16. The method of claim 15 , wherein at least 25% of the therapeutic agent contained in the non-durable coating is imparted into tissue of the vascular lumen within one hour of contracting the expandable structure.

17. The method of claim 10 , wherein the polymer matrix comprises a polymer selected from the group consisting of polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP) hydroxypropyl cellulose (HPC), methyl cellulose and hydroxypropyl methylcellulose, or a co-polymer of N-vinylpyrrolidone with a reactive double bond containing monomer.

18. The method of claim 10 , wherein paclitaxel is dispersed amongst non-covalently bound iodine within a polymer matrix comprising polyethylene glycol (PEG).

19. The method of claim 10 , further comprising withdrawing a protective sheath from over the expandable structure prior to expanding the expandable structure.

20. The method of claim 10 , further comprising contacting the non-durable coating against an atheroscolerotic or restenotic lesion.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0142 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0066 →
SECURITY INTEREST (REVOLVER) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0425 →
SECURITY INTEREST (TERM) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0506 →
RELEASE OF SECURITY INTEREST Recorded Dec 11, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: THE SPECTRANETICS CORPORATION
Reel/Frame 037268/0793 →
SECURITY INTEREST Recorded Jul 2, 2015
From: THE SPECTRANETICS CORPORATION
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 036055/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2015
From: COVIDIEN LP
To: THE SPECTRANETICS CORPORATION
Reel/Frame 035074/0106 →
MERGER Recorded Aug 9, 2013
From: CV INGENUITY LLC
To: COVIDIEN LP
Reel/Frame 030974/0870 →
CHANGE OF NAME Recorded Aug 9, 2013
From: CV INGENUITY CORP.
To: CV INGENUITY LLC
Reel/Frame 030994/0255 →